Artgen Biotech PJSC (MIC:ABIO) EBITDA Margin %: 22.11% (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIC:ABIO Artgen Biotech PJSC MIC:ABIO
17 GF Score
Price ₽44.46
View Full Analysis

What is Artgen Biotech PJSC EBITDA Margin %?

Artgen Biotech PJSC MIC:ABIO +0.50% 17 EBITDA Margin % is 22.11% as of Jun. 2023. GuruFocus rates MIC:ABIO with a GF Score™ of 17/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Artgen Biotech PJSC's EBITDA for the six months ended in Jun. 2023 was ₽137 Mil. Artgen Biotech PJSC's Revenue for the six months ended in Jun. 2023 was ₽621 Mil. Therefore, Artgen Biotech PJSC's EBITDA margin for the quarter that ended in Jun. 2023 was 22.11%.

Artgen Biotech PJSC  (MIC:ABIO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Artgen Biotech PJSC EBITDA Margin % Related Terms

Artgen Biotech PJSC EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Artgen Biotech PJSC's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artgen Biotech PJSC EBITDA Margin % Chart

Artgen Biotech PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.94 24.30 19.24 13.67 13.25

Artgen Biotech PJSC Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.58 12.86 19.13 8.29 22.11

MIC:ABIO vs VRTX, REGN, SGEN: EBITDA Margin % Comparison

For the Biotechnology subindustry, Artgen Biotech PJSC's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Artgen Biotech PJSC EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artgen Biotech PJSC's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Artgen Biotech PJSC's EBITDA Margin % falls into.


MIC:ABIO
17GF Score
Artgen Biotech PJSC MIC:ABIO
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artgen Biotech PJSC EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Artgen Biotech PJSC's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=150.598/1136.904
=13.25 %

Artgen Biotech PJSC's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=137.329/621.115
=22.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 22.11% mean?
Artgen Biotech PJSC (MIC:ABIO) has a EBITDA Margin % of 22.11% as of Jun. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Artgen Biotech PJSC and its competitors.
Is Artgen Biotech PJSC's EBITDA Margin % too high?
Artgen Biotech PJSC's current EBITDA Margin % is 22.11%. Overall, Artgen Biotech PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Artgen Biotech PJSC's EBITDA Margin % compare to VRTX and REGN?
Artgen Biotech PJSC's EBITDA Margin % of 22.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Artgen Biotech PJSC and its competitors. Artgen Biotech PJSC's current EBITDA Margin % is 22.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artgen Biotech PJSC stock overvalued right now?
Artgen Biotech PJSC (MIC:ABIO) has a current EBITDA Margin % of 22.11%. The current EBITDA Margin % is 22.11%. Artgen Biotech PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Artgen Biotech PJSC (MIC:ABIO), the current EBITDA Margin % is 22.11% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artgen Biotech PJSC Business Description

Address Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
17GF Score

Get the complete analysis for MIC:ABIO

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₽44.46
Price